New Treatment Strategies in Advanced Epidermal Growth Factor Receptor-Driven Non-Small Cell Lung Cancer: Beyond Single Agent Osimertinib.

Cancers (Basel) · 2025 · PMC11898774 · PMID 40075694

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Overall survival was a secondary endpoint, and data are not mature yet; however, a second interim analysis has been recently presented, showing a positive trend towards a median OS benefit in favor of the combination compared with osimertinib alone in the Asian cohort of the trial (40.5 versus 38.7 months) [ 28 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.